Tregitope Technology Could Become Autoimmune Treatment in Hands of Global Pharma Company
EpiVax has licensed its Tregitope technology — a new approach to harnessing the power of regulatory T-cells in autoimmune diseases such as systemic lupus erythematosus (SLE) — to an undisclosed global pharmaceutical company. The license will allow the company to enhance its existing drug development strategy for autoimmune diseases…